Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Caroline Lohrisch"'
Autor:
Maryam, Dosani, Sarah Nicole, Hamilton, Lovedeep, Gondara, Caroline, Speers, Rekha Manhas, Diocee, Alan, Nichol, Caroline, Lohrisch, Pauline, Truong
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 113:805-815
Locoregional recurrence risk and the role of locoregional radiation therapy (LRRT) in pN0(i+) and pN1mi breast cancer are unclear. This study compares locoregional relapse-free survival (LRRFS) in patients with pN0(i+) and pN1mi relative to pN0 and p
Autor:
Alan Nichol, Pauline T. Truong, Caroline Lohrisch, Theodora Koulis, Scott Tyldesley, Lovedeep Gondara, Caroline Speers, Lorna Weir, Robert Olson
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:1150-1158
Purpose This study evaluated long-term, population-based, breast cancer–specific outcomes in patients treated with radiation therapy (RT) to the breast/chest wall plus regional nodes using hypofractionated (HF) (40-42.5 Gy/16 fractions) versus conv
Autor:
Jorge Riera-Knorrenschild, Mounir Aout, Jose Perez-Garcia, Rosanne Serpanchy, Jozef Šufliarský, Christine Wohlfarth, Peter C. Thuss-Patience, Javier Cortes, Michelino De Laurentiis, Sylvie Lorenzen, Dina Sakaeva, Filippo Montemurro, Giacomo Allegrini, Véronique Diéras, Natsumi Irahara, Francesco Ricci, Caroline Lohrisch, Maria Vidal, Karen A. Gelmon, Eva Oravcová
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
JAMA Oncol
Universidad de Barcelona
JAMA Oncol
IMPORTANCE: ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. OBJECTIVE: To determine maximum tolerated doses (MTDs) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51bece98e9fb3e26d2f0f7a1460184b7
http://hdl.handle.net/2445/176631
http://hdl.handle.net/2445/176631
Autor:
Rachel B. Jimenez, Caroline Speers, Nathalie LeVasseur, Lovedeep Gondara, Caroline Lohrisch, Nafisha Lalani, Alan Nichol, K. David Voduc
Publikováno v:
International journal of radiation oncology, biology, physics. 109(1)
The predictive benefit of breast cancer molecular subtypes for systemic therapy approaches has been well established; yet, there is a paucity of data regarding their use as a predictor of radiation therapy fractionation sensitivity. The purpose of th
Autor:
Diego Villa, Pinaki Bose, Caroline Lohrisch, Carolyn Ch'ng, Wendie D. den Brok, Richard Corbett, Aly Karsan, Ian Bosdet, Howard John Lim, Tamara Shenkier, Sheridan Wilson, Richard A. Moore, Stephen Chia, Eric Y. Zhao, Karen A. Gelmon, Marco A. Marra, Daniel J. Renouf, Stephen Yip, Martin Jones, Yongjun Zhao, Erin Pleasance, Sophie Sun, Karen Mungall, Caralyn Reisle, Sreeja Leelakumari, Nina Thiessen, Kasmintan A. Schrader, Yaoqing Shen, Peter Eirew, Jacqueline E. Schein, Steven J.M. Jones, Andrew J. Mungall, Janessa Laskin, Yussanne Ma, Sean D. Young, Katayoon Kasaian
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(24)
Purpose: Recent studies have identified mutation signatures of homologous recombination deficiency (HRD) in over 20% of breast cancers, as well as pancreatic, ovarian, and gastric cancers. There is an urgent need to understand the clinical implicatio
Publikováno v:
Oncology. 61:73-82
Measurement of molecular markers predictive of response to therapy should enable more selective and effective utilization of anticancer agents. The predictive value of HER2 remains a complex and inconclusive subject. In metastatic breast cancer, HER2
Autor:
Caroline Lohrisch, Martine Piccart
Publikováno v:
Tumori Journal. 86:4-10
Autor:
David Cameron, Luc Dirix, M. Nooij, A. Hamilton, J.P. Lobelle, Robert Paridaens, Luc Duchateau, Laura Biganzoli, Caroline Lohrisch, Louk V.A.M. Beex, Tanja Cufer, Martine Piccart
Publikováno v:
Annals of Oncology, 14, 1391-8
Annals of Oncology, 14, 9, pp. 1391-8
Annals of Oncology, 14, 9, pp. 1391-8
Item does not contain fulltext BACKGROUND: Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c50e71f1b8480211f6288ce337bcc6
http://hdl.handle.net/2066/185095
http://hdl.handle.net/2066/185095
Autor:
Alan Hilary Calvert, P. Fargeot, Teresa Gamucci, R. Epelbaum, Peter F. Bruning, Laura Biganzoli, Caroline Lohrisch, Luc Duchateau, Robert E. Coleman, Tanja Cufer, Martine Piccart, Chris Twelves
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(14)
PURPOSE: To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as first-line chemotherapy for metastatic breast cancer. PATIENTS AND METHODS: Eligi
Autor:
Caroline Lohrisch, Martine Piccart
Publikováno v:
Clinical breast cancer. 2(2)
One of the current trends in breast cancer research is to identify markers that can predict response to specific anticancer therapies; intense laboratory research and therapeutic trials are exploiting this strategy. The combination of cytotoxic drugs